219 related articles for article (PubMed ID: 32714184)
1. Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
Shukla P; Goswami S; Keizer RJ; Winger BA; Kharbanda S; Dvorak CC; Long-Boyle J
Front Pharmacol; 2020; 11():888. PubMed ID: 32714184
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Long-Boyle JR; Savic R; Yan S; Bartelink I; Musick L; French D; Law J; Horn B; Cowan MJ; Dvorak CC
Ther Drug Monit; 2015 Apr; 37(2):236-45. PubMed ID: 25162216
[TBL] [Abstract][Full Text] [Related]
4. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
Takahashi T; Illamola SM; Jennissen CA; Long SE; Lund TC; Orchard PJ; Gupta AO; Long-Boyle JR
Transplant Cell Ther; 2022 Feb; 28(2):104.e1-104.e7. PubMed ID: 34883294
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
6. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
[TBL] [Abstract][Full Text] [Related]
7. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
8. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
[TBL] [Abstract][Full Text] [Related]
9. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing.
Hughes JH; Long-Boyle J; Keizer RJ
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):279-288. PubMed ID: 38520573
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Modeling and Simulation with Pharmacogenetic Insights Support the Relevance of Therapeutic Drug Monitoring for Myeloablative Busulfan Dosing in Adult HSCT.
Ben Hassine K; Seydoux C; Khier S; Daali Y; Medinger M; Halter J; Heim D; Chalandon Y; Schanz U; Nair G; Cantoni N; Passweg JR; Satyanarayana Uppugunduri CR; Ansari M
Transplant Cell Ther; 2024 Mar; 30(3):332.e1-332.e15. PubMed ID: 38081414
[TBL] [Abstract][Full Text] [Related]
11. Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen.
Bognàr TT; Kingma JSJ; Smeijsters EHE; van der Elst KCMK; de Kanter CTMK; Lindemans CAC; Egberts ACGT; Bartelink IHI; Lalmohamed AA
Bone Marrow Transplant; 2023 Jul; 58(7):762-768. PubMed ID: 37002411
[TBL] [Abstract][Full Text] [Related]
12. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
13. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Hill BT; Rybicki LA; Urban TA; Lucena M; Jagadeesh D; Gerds AT; Dean RM; Sobecks RM; Pohlman B; Bolwell B; Kalaycio ME; Hamilton BK; Copelan EA; Majhail NS
Biol Blood Marrow Transplant; 2020 Feb; 26(2):262-271. PubMed ID: 31610237
[TBL] [Abstract][Full Text] [Related]
15. A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.
Philippe M; Neely M; Bertrand Y; Bleyzac N; Goutelle S
Clin Pharmacokinet; 2017 Apr; 56(4):435-447. PubMed ID: 27585476
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
[TBL] [Abstract][Full Text] [Related]
17. Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?
Mehta PA; Emoto C; Fukuda T; Seyboth B; Teusink-Cross A; Davies SM; Wilhelm J; Fuller K; Vinks AA; Boulad F
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2416-2421. PubMed ID: 31326610
[TBL] [Abstract][Full Text] [Related]
18. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
Apsel Winger B; Shukla P; Kharbanda S; Keizer RJ; Goswami S; Cowan MJ; Dvorak CC; Long-Boyle J
Transplant Cell Ther; 2021 Mar; 27(3):258.e1-258.e6. PubMed ID: 33781528
[TBL] [Abstract][Full Text] [Related]
19. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients.
Ben Hassine K; Daali Y; Gloor Y; Nava T; Théorêt Y; Krajinovic M; Bittencourt H; Satyanarayana Uppugunduri CR; Ansari M
Ther Drug Monit; 2024 Jun; ():. PubMed ID: 38885146
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients.
van Hoogdalem MW; Emoto C; Fukuda T; Mizuno T; Mehta PA; Vinks AA
Br J Clin Pharmacol; 2020 May; 86(5):933-943. PubMed ID: 31851762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
